Browsing Tag
Bayer
19 posts
Bayer Leverkusen beat Freiburg to continue march towards the Bundesliga title
Bayer Leverkusen continued their march towards the Bundesliga title as they edged to victory at Freiburg to restore their 10-point lead at the top. Xabi Alonso’s side remain unbeaten in the league this season and ran out 3-2 winners on Sunday afternoon. Leverkusen remain on course to end Bayern Munich’s run of 11 successive titles
Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes
Not intended for U.S. and UK Media Berlin, June 22, 2023 – Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double blind parallel-group Phase III study to evaluate the efficacy and safety of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D). The primary objective
Bayer sees more than doubling of accessible markets and potential to shape regenerative agriculture on more than 400 million acres
New York, June 20, 2023 – Bayer today announced its Crop Science Division will capitalize on opportunities presented by the shift to regenerative agriculture to grow in adjacent markets in addition to its core business of seeds, traits, crop protection and digital. At its 2023 Innovation Summit, the company identified growth potential in segments like
Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
Not intended for U.S. and UK Media Berlin, June 5, 2023 – Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
Berlin, May 16, 2023 – Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment to prevent stroke and systemic embolism in people with atrial fibrillation (AF). This news follows asundexian’s first U.S. FDA Fast Track Designation for the
Roma v Bayer 04 Leverkusen: Jose Mourinho relishing Xabi Alonso reunion in Europa League
Roma 1-0 Bayer 04 Leverkusen: Jose Mourinho's side earn first-leg advantageLast updated on 11 May 2023.From the section European FootballEdoardo Bove's goal was his first in a European competitionEdoardo Bove's second-half goal gave Jose Mourinho's Roma the advantage over Bayer Leverkusen after the first leg of their Europa League semi-final. The 20-year-old passed into the
10 May 2023 | 09:59 AM Europe/Amsterdam Not intended for U.S. and UK Media Summary Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) / Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related
Bayer pledges to help tackle global water crisis with new water strategy
Leverkusen, March 21, 2023 – Bayer is launching its new water strategy at the UN 2023 Water Conference in New York. The company is making water an integral part of its business decisions, investments and selection of suppliers. Bayer's water strategy reflects its position as a key player in the fields of health and agriculture
Bayer collaborates with Microsoft to unveil new cloud-based enterprise solutions, advancing innovation and transparency in the agri-food industry
San Francisco / California, March 14, 2023 – Following a 2021 strategic partnership announcement with Microsoft, Bayer today launched new cloud-based solutions for the agri-food industry: AgPowered Services from Bayer in combination with the new Microsoft Azure Data Manager for Agriculture provide ready-to-use capabilities available for businesses and organizations from start-ups to global enterprises to
Bayer submits aflibercept 8 mg for marketing authorization in Japan
01 March 2023 | 07:59 AM Europe/Amsterdam Not intended for U.S. and UK Media Summary Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PULSAR and